Standard BioTools signs definitive agreement to sell mass cytometry business to Multiplex Bio Inc.

STANDARD BIOTOOLS INC.

Agreement dated July 28, 2026, for sale of mass cytometry business (CyTOF, Hyperion, Maxpar, Theia platforms) to Multiplex Bio Inc.
Consideration includes Base Seller Note and Seller Working Capital Note; additional contingent consideration tied to Qualifying Exit.
Sale subject to stockholder approval, regulatory clearances, and other customary conditions.
Concurrently, Standard BioTools is pursuing acquisition of Treeline and potential sale of microfluidics business.
Definitive agreement includes transition services, IP assignments, and other ancillary documents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.